Marco Exams automatically processes lymph node biopsies, extensive IHC, FISH, NGS and flow cytometry results in Lymphoma to generate differential diagnoses, prognostic stratification and therapeutic suggestions. The system transforms laboratory and pathology reports into structured, evidence-based clinical recommendations.
Some answers to questions we often receive
Marco Exams integrates lymph node biopsies, extensive IHC, FISH, NGS and flow cytometry results for Lymphoma, including immunohistochemistry, FISH, next-generation sequencing (NGS), liquid biopsy (ctDNA) and imaging results when available in structured format, generating integrated clinical interpretation of all results.
Yes. Marco Exams connects via standard APIs (HL7 FHIR, ASTM) with leading LIS and LIMS systems. The integration allows Lymphoma exam reports to flow automatically into Marco Exams, generating real-time clinical interpretation without manual intervention.
Yes. Marco Exams identifies Lymphoma result patterns requiring urgent clinical action — an acquired resistance mutation, a molecular result indicating ineligibility for a planned therapy, or an unexpected actionable alteration — and generates directed alerts to the treating physician.
Marco Exams has an interpretation engine trained on Lymphoma-specific biomarkers: CD20, CD3, Ki-67, BCL2/BCL6/MYC translocations, IgHV and mutational status. For each marker, the system knows positivity thresholds per international guidelines, current therapeutic implications and complementary testing recommendations when results are borderline or unexpected.
Marco Exams' evidence engine updates continuously with reference guidelines for Lymphoma and published clinical trial data. FDA and EMA approvals and NCCN/ESMO guideline changes are systematically incorporated into the interpretation engine.
Marco Exams generates structured reports in PDF or web format, designed for direct presentation at Lymphoma tumor boards. The report integrates all patient exam results, clinical interpretation, prognostic stratification and recommended therapeutic options with their evidence sources.
Extensive IHC panels in lymphoma and their WHO 2022 classification require integration of multiple markers that consumes valuable pathology time.